Skip to main content

news

Shardul Amarchand Mangaldas & Co. and Goodwin Procter have advised Biocon Biologics, a subsidiary of Indian drugmaker Biocon, in its $3.34 billion acquisition of the biosimilars business of U.S.-based Viatris, which was counseled by Cravath, Swaine & Moore, and Saraf and Partners.

According to Reuters, the deal will expand Biocon's biosimilars portfolio of 20 treatments by adding therapies used for treating diabetes, tumors and autoimmune diseases and commercialising them for developed markets.

Viatris will get up to $2.34 billion in cash, and convertible shares in Biocon Biologics worth $1 billion, Reuters added.

The SAM team was led by partners Iqbal Khan and Ambarish, while the Goodwin Procter team was led by partners Graham Defries and Michael R. Patrone. Partner Mohit Saraf led the Saraf and Partners team, while the Cravath team was led by partners Mark Greene and Aaron Gruber.

Related Articles

Deals

N&A, S&C, TMI advise as Japan's Nidec makes $1.6 bln bid for Makino Milling

by Asian Legal Business《亚洲法律杂志》 |

TMI Associates, Freshfields and Davis Polk & Wardwell have represented Japanese manufacturing giant Nidec on its 257-billion-yen ($1.6 billion) bid for Makino Milling Machine, which turned to Nishimura & Asahi and Sullivan & Cromwell for advice.

Deals

N&A, MHM, Skadden, STB guide JX Advanced Metal’s $3 bln Japan IPO

by Nimitt Dixit |

Nishimura & Asahi and Skadden Arps Slate Meagher & Flom are advising JX Advanced Metals on its upcoming 460-billion-yen ($3 billion) initial public offering, the largest listing in Japan since SoftBank Corp’s $23.5 billion IPO in 2018.

Deals

Trilegal, Touchstone, CAM act on Carlyle’s $400 mln entry into India auto-components space

by Nimitt Dixit |

Trilegal has advised global private equity firm Carlyle on its acquisition of majority stakes in Highway Industries (HIL) and Roop Automotives for $400 million, marking its entry into India's auto components sector through a new manufacturing platform.